Table 1.
Patient characteristics.
| Characteristic | Number (%) | p-value | ||
|---|---|---|---|---|
| Adjuvant TKI (n = 30) | Dose interruption (n = 9) | Non-shift interval (n = 21) | ||
| Sex | – | – | – | – |
| Male | 9 (30%) | 5 (17%) | 4 (13%) | 0.082 |
| Female | 21 (70%) | 4 (13%) | 17 (56%) | 0.082 |
| Age | – | – | – | – |
| Mean ± SD | 65.3 ± 11.7 | 68.8 ± 11.3 | 63.8 ± 11.8 | – |
| Median (Min to Max) | 65.5 (40 to 83) | 68 (48 to 81) | 63 (40 to 83) | – |
| Smoking | – | – | – | – |
| Never | 28 (93%) | 7 (23%) | 21 (70%) | 0.083 |
| Former | 1 (3%) | 1 (3%) | 0 (0%) | 0.300 |
| Current | 1 (3%) | 1 (3%) | 0 (0%) | 0.300 |
| Pathologic stage (AJCC 8th) | – | – | – | – |
| Stage II | 4 (13%) | 1 (3%) | 3 (10%) | >0.999 |
| Stage IIA | 1 (3%) | 1 (3%) | 0 (0%) | 0.300 |
| Stage IIB | 3 (10%) | 0 (%) | 3 (10%) | 0.535 |
| Stage III | 26 (86%) | 8 (27%) | 18 (60%) | >0.999 |
| Stage IIIA | 19 (63%) | 5 (16%) | 14 (46%) | 0.687 |
| Stage IIIB | 7 (23%) | 3 (10%) | 4 (13%) | 0.640 |
| EGFR TKI Medication | – | – | – | – |
| Gefitinib | 25 (83%) | 4 (13%) | 12 (40%) | 0.694 |
| Erlotinib | 3 (10%) | 1 (3%) | 2 (7%) | >0.999 |
| Afatinib | 2 (%) | 0 (%) | 2 (7%) | >0.999 |
| Medication shift | 9 (30%) | 4 (13%) | 5 (17%) | 0.389 |
| Mutation Type | – | – | – | – |
| Exon 21 L858R | 14 (46%) | 6 (20%) | 8 (27%) | 0.109 |
| Exon 19 | 11 (37%) | 2 (6%) | 9 (30%) | 0.262 |
| Exon 18 | 1 (3%) | 0 (%) | 1 (3%) | >0.999 |
| Rare mutation | 4 (12%) | 1 (%) | 3 (10%) | >0.999 |
| Disease Progression Site | – | – | – | – |
| Brain | 5 (17%) | 4 (10%) | 1 (13%) | 0.19 |
| Lymph node progression | 1 (3%) | 0 (0%) | 1 (3%) | >0.999 |
| Pleural seeding | 1 (3%) | 0 (0%) | 1 (3%) | >0.999 |
| Lung to lung metastasis | 1 (3%) | 1 (3%) | 0 (0%) | >0.999 |
| Duration of treatment (months) | – | – | – | – |
| Mean ± SD | 52.7 ± 32.0 | – | – | – |
| Median (Min to Max) | 44.5 (6~133) | – | – | – |